Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Schizophrenia - Pipeline Review, H2 2013 market report to its offering
Schizophrenia - Pipeline Review, H2 2013
, 'Schizophrenia - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Schizophrenia. Schizophrenia - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Schizophrenia.
- A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Schizophrenia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Bristol-Myers Squibb Company
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Neurocrine Biosciences, Inc.
EGIS Pharmaceuticals Plc
Gedeon Richter Plc.
H Lundbeck A/S
Les Laboratoires Servier
Zydus Cadila Healthcare Limited
XTL Biopharmaceuticals Ltd.
GW Pharmaceuticals plc
Paladin Labs Inc.
ACADIA Pharmaceuticals Inc.
Dongwha Pharm Co., Ltd.
Biotie Therapies Corp.
Suven Life Sciences Ltd.
Newron Pharmaceuticals S.p.A.
DONGKOOK Pharmaceutical Co., Ltd.
Jiangsu Nhwa Pharma Corporation
Intas Pharmaceuticals Ltd.
Spectrum Pharmaceuticals, Inc.
Critical Pharmaceuticals Limited
AGY Therapeutics, Inc.
Fabre-Kramer Pharmaceuticals, Inc.
Siena Biotech S.p.A.
Laboratorios Farmaceuticos ROVI, S.A.
Intra-Cellular Therapies, Inc.
Vanda Pharmaceuticals Inc.
Adamed Sp. z o.o.
Heptares Therapeutics Ltd.
Ascendis Pharma A/S
Reviva Pharmaceuticals Inc.
Promentis Pharmaceuticals, Inc.
To view the table of contents for this market research report please visit